SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of Hepatitis C in chronic kidney disease. Kidney Int 2008;73(Suppl 109):S199.
  • 2
    Uhlig K, MacLeod A, Craig J et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006;70:205865.
  • 3
    Fukagawa M, Tsukamoto Y, Tsubakihara Y et al. On the evaluation of evidence levels and degrees of guideline recommendation. J Jpn Soc Dial Ther 2010;43:3479.

REFERENCES

REFERENCES

  • 1
    Espinosa M, Martin-Malo A, Alvarez de Lara MA, Soriano S, Aljama P. High ALT levels predict viremia in anti-HCV-positive HD patients if a modified normal range of ALT is applied. Clin Nephrol 2000;54:1516.
  • 2
    Alric L, Di-Martino V, Selves J et al. Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology 2002;123:14949.
  • 3
    Cotler SJ, Diaz G, Gundlapalli S et al. Characteristics of hepatitis C in renal transplant candidates. J Clin Gastroenterol 2002;35:1915.
  • 4
    Schiavon LL, Schiavon JL, Filho RJ et al. Simple blood tests as noninvasive markers of liver fibrosis in hemodialysis patients with chronic hepatitis C virus infection. Hepatology 2007;46:30714.
  • 5
    Trevizoli JE, de Paula Menezes R, Ribeiro Velasco LF et al. Hepatitis C is less aggressive in hemodialysis patients than in nonuremic patients. Clin J Am Soc Nephrol 2008;3:138590.
  • 6
    Hu KQ, Lee SM, Hu SX, Xia VW, Hillebrand DJ, Kyulo NL. Clinical presentation of chronic hepatitis C in patients with end-stage renal disease and on hemodialysis versus those with normal renal function. Am J Gastroenterol 2005;100:20108.
    Direct Link:
  • 7
    Sterling RK, Sanyal AJ, Luketic VA et al. Chronic hepatitis C infection in patients with end stage renal disease: characterization of liver histology and viral load in patients awaiting renal transplantation. Am J Gastroenterol 1999;94:357682.
    Direct Link:
  • 8
    Becker VR, Badiani RG, Lemos LB et al. Factors associated with the progression of hepatic fibrosis in end-stage kidney disease patients with hepatitis C virus infection. Eur J Gastroenterol Hepatol 2009;21:13959.
  • 9
    de Paula Farah K, Carmo RA, de Figueiredo Antunes CM et al. Hepatitis C, HCV genotypes and hepatic siderosis in patients with chronic renal failure on haemodialysis in Brazil. Nephrol Dial Transplant 2007;22:202731.
  • 10
    Martin P, Carter D, Fabrizi F et al. Histopathological features of hepatitis C in renal transplant candidates. Transplantation 2000;69:147984.
  • 11
    Pol S, Romeo R, Zins B et al. Hepatitis C virus RNA in anti-HCV positive hemodialyzed patients: significance and therapeutic implications. Kidney Int 1993;44:1097100.
  • 12
    Mathurin P, Mouquet C, Poynard T et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999;29:25763.
  • 13
    Gentil MA, Rocha JL, Rodríguez-Algarra G et al. Impaired kidney transplant survival in patients with antibodies to hepatitis C virus. Nephrol Dial Transplant 1999;14:245560.
  • 14
    Zylberberg H, Nalpas B, Carnot F et al. Severe evolution of chronic hepatitis C in renal transplantation: a case control study. Nephrol Dial Transplant 2002;17:12933.
  • 15
    Caramelo C, Ortiz A, Aguilera B et al. Liver disease patterns in hemodialysis patients with antibodies to hepatitis C virus. Am J Kidney Dis 1993;22:8228.
  • 16
    Al-Wakeel J, Malik GH, Al-Mohaya S et al. Liver disease in dialysis patients with antibodies to hepatitis C virus. Nephrol Dial Transplant 1996;11:22658.
  • 17
    Pawa S, Ehrinpreis M, Mutchnick M, Janisse J, Dhar R, Siddiqui FA. Percutaneous liver biopsy is safe in chronic hepatitis C patients with end-stage renal disease. Clin Gastroenterol Hepatol 2007;5:131620.
  • 18
    Simon N, Couroucé AM, Lemarrec N, Trépo C, Ducamp S. A twelve year natural history of hepatitis C virus infection in hemodialyzed patients. Kidney Int 1994;46:50411.
  • 19
    Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ et al. Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol 2007;18:158493.
  • 20
    Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000;11:1896902.
  • 21
    Stehman-Breen CO, Emerson S, Gretch D, Johnson RJ. Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis 1998;32:62934.
  • 22
    Pereira BJ, Natov SN, Bouthot BA et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int 1998;53:137481.
  • 23
    Goodkin DA, Bragg-Gresham JL, Koenig KG et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003;14:32707.
  • 24
    Di Napoli A, Pezzotti P, Di Lallo D, Petrosillo N, Trivelloni C, Di Giulio S, Lazio Dialysis Registry. Epidemiology of hepatitis C virus among long-term dialysis patients: a 9-year study in an Italian region. Am J Kidney Dis 2006;48:62937.
  • 25
    Nakai S, Shinzato T, Sanaka T et al. The Current State of Chronic Dialysis Treatment in Japan (as of December 31, 2000). Ther Apher Dial 2002;7:335.
  • 26
    Fabrizi F, Takkouche B, Lunghi G, Dixit V, Messa P, Martin P. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat 2007;14:697703.
  • 27
    Al Meshari K, al Ahdal M, Alfurayh O, Ali A, De Vol E, Kessie G. New insights into hepatitis C virus infection of hemodialysis patients: the implications. Am J Kidney Dis 1995;25:5728.
  • 28
    Akiba T, Kawaguchi Y, Kuroda M et al. Investigation of the real state of HCV infection at Japanese dialysis facilities. J Jpn Soc Dial Ther 1994;27:277782.
  • 29
    Okuda K, Yokosuka O. Natural history of chronic hepatitis C in patients on hemodialysis: case control study with 4–23 years of follow-up. World J Gastroenterol 2004;10:220912.
  • 30
    Ishida H, Agishi T, Koyama I et al. Hemodialysis paradox: survey on the incidence rate of hepatocellular carcinoma in antihepatitis virus C-antibody-positive chronic hemodialysis patients. Artif Organs 2001;25:5860.
  • 31
    Espinosa M, Martin-Malo A, Alvarez de Lara MA, Aljama P. Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients. Nephrol Dial Transplant 2001;16:166974.
  • 32
    Yoshida H, Shiratori Y, Moriyama M et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999;131:17481.
  • 33
    Buccianti G, Maisonneuve P, Ravasi B, Cresseri D, Locatelli F, Boyle P. Cancer among patients on renal replacement therapy: a population-based survey in Lombardy, Italy. Int J Cancer 1996;66:5913.
  • 34
    Iseki K, Osawa A, Fukiyama K. Evidence for increased cancer deaths in chronic dialysis patients. Am J Kidney Dis 1993;22:30813.
  • 35
    Furusyo N, Hayashi J, Kanamoto-Tanaka Y et al. Liver damage in hemodialysis patients with hepatitis C virus viremia: a prospective 10-year study. Dig Dis Sci 2000;45:22218.
  • 36
    Japanese Society for Dialysis Therapy. Present state of chronic dialysis therapy in Japan (as of December 31, 1999). 2001;34:131.
  • 37
    Rampino T, Arbustini E, Gregorini M et al. Hemodialysis prevents liver disease caused by hepatitis C virus: role of hepatocyte growth factor. Kidney Int 1999;56:228691.
  • 38
    Furusyo N, Hayashi J, Ariyama I et al. Maintenance hemodialysis decreases serum hepatitis C virus (HCV) RNA levels in hemodialysis patients with chronic HCV infection. Am J Gastroenterol 2000;95:4906.
    Direct Link:
  • 39
    Azevedo HA, Villela-Nogueira CA, Perez RM et al. Similar HCV viral load levels and genotype distribution among end-stage renal disease patients on hemodialysis and HCV-infected patients with normal renal function. J Nephrol 2007;20:60916.
  • 40
    Butt AA, Evans R, Skanderson M, Shakil AO. Comorbid medical and psychiatric conditions and substance abuse in HCV infected persons on dialysis. J Hepatol 2006;44:8648.
  • 41
    Matsumura H, Moriyama M, Goto I, Tanaka N, Okubo H, Arakawa Y. Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C—a study of 527 patients at one establishment. J Viral Hepat 2000;7:26875.
  • 42
    Nishida C, Uto H, Oketani M et al. Clinical significance of alanine aminotransferase levels and the effect of ursodeoxycholic acid in hemodialysis patients with chronic hepatitis C. J Gastroenterol 2010;45:32634.
  • 43
    Odagiri E, Jibiki K, Takeda M et al. Effect of hemodialysis on the concentration of the seven tumor markers carcinoembryonic antigen, alpha-fetoprotein, squamous cell carcinoma-related antigen, neuron-specific enolase, CA125, CA19-9 and CA15-3 in uremic patients. Am J Nephrol 1991;11:3638.
  • 44
    Kato A, Yasuda H, Togawa A et al. Measurement of des-gamma-carboxy prothrombin levels in hemodialysis patients positive for anti-hepatitis virus C antibody. Clin Nephrol 2002;58:296300.
  • 45
    Ando R, Akiba T. Present state of preventive measures against nosocomial hepatitis virus infections at hemodialysis facilities. J Jpn Soc Dial Ther 2009;42:42333.
  • 46
    Gordon CE, Balk EM, Becker BN et al. KDOQI US commentary on the KDIGO clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in CKD. Am J Kidney Dis 2008;52:81125.
  • 47
    Japan Society of Hepatology, ed. Guidelines for the Treatment of Chronic Hepatitis 2008. Tokyo: Bunkodo, 2008.
  • 48
    Clemente MG, Congia M, Lai ME et al. Effect of iron overload on the response to recombinant interferon-alfa treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C. J Pediatr 1994;125:1238.
  • 49
    Kato J, Miyanishi K, Kobune M et al. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J Gastroenterol 2007;42:8306.
  • 50
    Caramelo C, Albalate M, Bermejillo T et al. Relationships between plasma ferritin and aminotransferase profile in haemodialysis patients with hepatitis C virus. Nephrol Dial Transplant 1996;11:17926.
  • 51
    Kurihara I, Saito T. Significance of intravenous iron injection therapy in HCV-antibody-positive dialysis patients. J Jpn Soc Nephrol 2002;44:38995.
  • 52
    Kato A, Odamaki M, Nakamura H, Yodoi J, Hishida A. Elevation of blood thioredoxin in hemodialysis patients with hepatitis C virus infection. Kidney Int 2003;63:22628.
  • 53
    Altintepe L, Kurtoglu E, Tonbul Z, Yeksan M, Yildiz A, Türk S. Lower erythropoietin and iron supplementation are required in hemodialysis patients with hepatitis C virus infection. Clin Nephrol 2004;61:34751.
  • 54
    Japanese Society for Dialysis Therapy. 2008 edition of the Guidelines for the Treatment of Renal Anemia in Patients with Chronic Kidney Disease, Japanese Society for Dialysis Therapy. J Jpn Soc Dial Ther 2008;41:661716.

REFERENCES

REFERENCES

  • 1
    Casanovas-Taltavull T, Baliellas C, Benasco C et al. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation. Am J Gastroenterol 2001;96:11707.
  • 2
    Degos F, Pol S, Chaix ML et al. The tolerance and efficacy of interferon-alpha in hemodialysis patients with HCV infection: a multicentre, prospective study. Nephrol Dial Transplant 2001;16:101723.
  • 3
    Rocha CM, Perez RM, Ferreira AP et al. Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis. Liver Int 2006;26:30510.
  • 4
    Buargub M, El Huni S, Tagdi M. Tolerance and efficacy of interferon-alpha in hemodialysis patients in Tripoli. Saudi J Kidney Transplant 2006;17:33843.
  • 5
    Yildirim B, Durak H, Ozaras R et al. Liver steatosis in hepatitis C positive hemodialysis patients and factors affecting IFN-2a treatment. Scand J Gastroenterol 2006;41:123541.
  • 6
    Fabrizi F, Dixit V, Messa P, Martin P. Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J Viral Hepat 2008;15:7988.
  • 7
    Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB. Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms. Am J Kidney Dis 2008;51:26377.
  • 8
    Uchihara M, Izumi N, Sakai Y et al. Interferon therapy for chronic hepatitis C in hemodialysis patients: increased serum levels of interferon. Nephron 1998;80:516.
  • 9
    Zeniya M, Yokoyama K, Imamura N et al. Significance of interferon-β for the treatment of hepatitis C virus infection in hemodialyzed patients. Hepatol Res 2010;40:8629.
  • 10
    Nakayama H, Shiotani S, Akiyama S, Gotoh H, Tani M, Akine Y. Pharmacokinetic study of human natural beta-interferon in patients with end-stage renal failure. Clin Nephrol 2001;56:3826.
  • 11
    Nakajima F, Fukii M, Kitamura T et al. A case report of interferon beta monotherapy for high hepatitis C viral load in dialysis patients. Ther Apher Dial 2007;11:3068.
  • 12
    Umeda S, Minami H, Izumi N, Yamamoto M, Kanno T, Ozaki Y. Treatment of a hemodialysis patient with hepatitis C using interferon β. J Jpn Soc Dial Ther 1994;27:638.
  • 13
    Tachibana N, Ako S, Deura T et al. A dialysis patient treated with interferon β for chronic hepatitis C: Pharmacokinetic evaluation of IFNβ. J Jpn Soc Dial Ther 2000;33:617.
  • 14
    Araoka T, Takeoka H, Nishioka K et al. Evaluation of safe and effective interferon β therapy for maintenance hemodialysis patients with chronic hepatitis C. J Jpn Soc Dial Ther 2009;42:393402.
  • 15
    Teta D, Luscher BL, Gonvers JJ, Francioli P, Phan O, Burnier M. Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients. Nephrol Dial Transplant 2005;20:9913.
  • 16
    Sporea I, Popescu A, Sirli R et al. Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis. World J Gastroenterol 2006;12:41914.
  • 17
    Covic A, Maftei ID, Mardare NG et al. Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit. J Nephrol 2006;19:794801.
  • 18
    Kokoglu OF, Ucmak H, Hosoglu S et al. Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J Gastroenterol Hepatol 2006;21:57580.
  • 19
    Chan TM, Ho SK, Tang CS et al. Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection. Nephrology (Carlton) 2007;12:117.
  • 20
    Casanovas-Taltavull T, Baliellas C, Llobet M et al. Preliminary results of treatment with pegylated interferon alpha 2A for chronic hepatitis C virus in kidney transplant candidates on hemodialysis. Transplant Proc 2007;39:21257.
  • 21
    Ayaz C, Celen MK, Yuce UN, Geyik MF. Efficacy and safety of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. World J Gastroenterol 2008;14:2559.
  • 22
    Akhan SC, Kalender B, Ruzgar M. The response to pegylated interferon alpha 2a in haemodialysis patients with hepatitis C virus infection. Infection 2008;36:3414.
  • 23
    Russo MW, Ghalib R, Sigal S, Joshi V. Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2006;21:43743.
  • 24
    Tan SS, Abu Hassan MR, Abdullah A et al. Treatment of hemodialysis (HD) patients with chronic hepatitis C (CHC) using an escalating dose regimen of pegylated interferon (PEG-IFN) alpha-2b. Hepatology 2007;46:363a4a.
  • 25
    Liu CH, Liang CC, Lin JW et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomized study. Gut 2007;57:52530.
  • 26
    Chugai Pharmaceutical. Pegasys Drug Interview Form (10th revised edition). p23, 2008.
  • 27
    Akiba T, Kikuchi K. A study of the efficacy and administration method of peg-interferon-α-2a preparations in patients with chronic hepatitis C undergoing chronic hemodialysis. A Grant-in-Aid by the Ministry of Health, Labour and Welfare for research regarding the epidemiology of hepatitis B and C and measures to control hepatitis including mass screening, a research project on emergency measures to conquer hepatitis and other diseases. 2005 Assigned Research Report; 511, 2006.
  • 28
    Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat 2006;13:31621.
  • 29
    Rendina M, Schena A, Castellaneta NM et al. The treatment of chronic hepatitis C with peginterferon alfa-2a (40kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol 2007;46:76874.
  • 30
    van Leusen R, Adang RP, de Vries RA et al. Pegylated interferon alfa-2a (40kD) and ribavirin in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2008;23:7215.
  • 31
    Carriero D, Fabrizi F, Uriel AJ, Park J, Martin P, Dieterich DT. Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin. Int J Artif Organs 2008;31:295302.
  • 32
    MSD. Rebetol Drug Interview Form (3rd revised edition). p2, 2005.
  • 33
    Kumada H. Long-term treatment of chronic hepatitis C with glycyrrhizin [stronger neo-minophagen C (SNMC)] for preventing liver cirrhosis and hepatocellular carcinoma. Oncology 2002;62:94100.
  • 34
    Omata M, Yoshida H, Toyota J et al. Japanese C-Viral Hepatitis Network. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. Gut 2007;56:174753.
  • 35
    Fujiwara K, Kaneko S, Kakumu S et al. The Virus Reduction Therapy Study Group. Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load. Hepatol Res 2007;37:70110.
  • 36
    Mathurin P, Mouquet C, Poynard T. Impact of hepatitis B and C virus on kidney transplant outcome. Hepatology 1999;29:25763.
  • 37
    Fabrizi F, Martin P, Dixit V, Bunnapradist S, Kanwal F, Dulai G. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies. Am J Transplant 2005;5:243340.
  • 38
    Kamar N, Toupance O, Buchler M et al. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 2003;14:20928.
  • 39
    Cruzado JM, Casanovas-Taitavull T, Torras J. Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance. Am J Transplant 2003;3:35760.
  • 40
    Mahmoud IM, Sobh MA, El-Habashi AF et al. Interferon therapy in hemodialysis patients with chronic hepatitis C: study of tolerance, efficacy and post-transplantation course. Nephron Clin Pract 2005;100:1339.
  • 41
    Fabrizi F, Lunghi G, Dixit V, Martin P. Meta-analysis: anti-viral therapy of hepatitis C virus-related liver disease in renal transplant patients. Aliment Pharmacol Ther 2006;24:141322.

REFERENCES

  • 1
    Kokubo S, Horii T, Yonekawa O, Ozawa N, Mukaide M. A phylogenetic-tree analysis elucidating nosocomial transmission of hepatitis C virus in a haemodialysis unit. J Viral Hepat 2002;9:4504.
  • 2
    Furusyo N, Kubo N, Nakashima H, Kashiwagi K, Etoh Y, Hayashi J. Confirmation of Nosocomial Hepatitis C Virus Infection in a hemodialysis unit. Infect Control Hosp Epidemiol 2004;25:58490.
  • 3
    Noiri E, Nakao A, Oya A, Fujita T, Kimura S. Hepatitis C virus in blood and dialysate in hemodialysis. Am J Kidney Dis 2001;37:3842.
  • 4
    Stramer SL, Glynn SA, Kleinman SH et al. National Heart, Lung, and Blood Institute Nucleic Acid Test Study Group. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004;351:7608.
  • 5
    Alter HJ, Aragon T, AuBuchon JP et al. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998;47(RR19):139.
  • 6
    Bailey JL, Balter P, Berns J et al. Recommendations for preventing transmission of infection among chronic hemodialysis patients. MMWR 2004;50(RR05):143.
  • 7
    Manual Regarding the Standard Dialysis Procedure and Prevention of Nosocomial Infections in Dialysis Medicine (3rd revised edition). Research Project on Emergency Measures to Overcome Hepatitis and Other Diseases on a Grant-in-Aid for Health, Labour and Welfare Science 2007, Tokyo, 2007
  • 8
    Deutschen Arbeitsgemeinschaft für Klinische Nephrologie e.V. in Zusammenarbeit mit dem Verband Deutscher Nierenzentren der DD nÄ e.V. sowie der Arbeitsgemeinschaft für Pädiatrische Nephrologie (APN). Dialysestandard 2006.
  • 9
    Fissell RB, Bragg-Gresham JL, Woods JD et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2004;65:233542.
  • 10
    dos Santos JP, Loureiro A, Cendoroglo Neto M, Pereira BJ. Impact of dialysis room and reuse strategy on the incidence of hepatitis C virus infection in haemodialysis units. Nephrol Dial Transplant 1996;11:201722.
  • 11
    Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000;11:1896902.
  • 12
    Ando R, Akiba T. Present state of preventive measures against nosocomial infection of viral hepatitis at hemodialysis facilities. J Jpn Soc Dial Ther 2009;42:42333.
  • 13
    Tsuruta Y, Watanabe U, Yamazaki C, Maeda K. Present state of hepatitis B and C infection at dialysis facilities in Aichi Prefecture (Part 2). J Jpn Assoc Dial Physicians 2002;17:4229.
  • 14
    Arenas MD, Sanchez-Paya J, Barril G et al. A multicentric survey of the practice of hand hygine in haemodialysis units: factors affecting compliance. Nephrol Dial Transplant 2005;20:116471.
  • 15
    Delarocque-Astagneau E, Baffoy N, Thiers V et al. Outbreak of hepatitis C virus infection in a hemodialysis unit: potential transmission by the hemodialysis machine? Infect Control Hosp Epidemiol 2002;23:32834.
  • 16
    Izopet J, Pasquier C, Sandres K, Puel J, Rostaing L. Molecular evidence for nosocomial transmission of hepatitis C virus in a French hemodialysis unit. J Med Virol 1999;58:13944.